drugset / Trial / NCT01265264
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral Ulodesine Added to Allopurinol
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine whether ulodesine and allopurinol combined for 12 weeks are effective in treating gout in patients who are not adequately responding to allopurinol alone.
Timeline
- Start
- 2010-12
- Primary completion
- 2012-07
- Completion
- 2013-02
Outcome
Met primary endpoint
release “The primary endpoint of the study was successfully achieved. When added to allopurinol 300 mg, BCX4208 was superior to allopurinol plus placebo” biocryst.com ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ulodesine | Small molecule | 5 mg | Oral |
| Subject | Ulodesine | Small molecule | 10 mg | Oral |
| Subject | Ulodesine | Small molecule | 20 mg | Oral |
| Subject | Ulodesine | Small molecule | 40 mg | Oral |